Summary
Signal counts
Assets tracked: 9
Watchlist assets: 6
Registry stop assets: 0
Sponsor overview
AstraZeneca
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07181161 | https://clinicaltrials.gov/study/NCT06219941 | https://clinicaltrials.gov/study/NCT01625286 | https://clinicaltrials.gov/study/NCT00372944 | https://clinicaltrials.gov/study/NCT05460273 | https://clinicaltrials.gov/study/NCT02558894 | https://clinicaltrials.gov/study/NCT03944772 | https://clinicaltrials.gov/study/NCT04538742 | https://clinicaltrials.gov/study/NCT06533826 | https://clinicaltrials.gov/study/NCT07428044 | https://clinicaltrials.gov/study/NCT06535607
Assets
Linked programs
- AZD0516: Low Signal (0/5)
- AZD0901: Operational Burden Signal (2/5)
- AZD5363 when combined with weekly paclitaxel.: Low Signal (1/5)
- AZD6244: Results Not Found Signal (2/5)
- Datopotamab Deruxtecan (Dato-DXd): Watchlist Signal (2/5)
- MEDI4736 monotherapy: Low Signal (0/5)
- Osimertinib: Timeline Staleness Signal (4/5)
- Trastuzumab deruxtecan: Operational Burden Signal (3/5)
- Volrustomig: Watchlist Signal (2/5)